Financhill
Sell
35

ESLOY Quote, Financials, Valuation and Earnings

Last price:
$139.39
Seasonality move :
4.1%
Day range:
$137.74 - $141.43
52-week range:
$103.41 - $155.46
Dividend yield:
0%
P/E ratio:
50.68x
P/S ratio:
4.52x
P/B ratio:
3.03x
Volume:
34.9K
Avg. volume:
40.2K
1-year change:
25.62%
Market cap:
$127.3B
Revenue:
$28.7B
EPS (TTM):
$2.75

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ESLOY
Essilorluxottica
-- -- -- -- --
CLLS
Cellectis SA
$13.8M -- 204.72% -100% $5.80
DBVT
DBV Technologies SA
$501.4K -$0.24 -- -87.95% $15.52
GNFT
Genfit SA
$151.2M -- -- -- $10.17
IPHA
Innate Pharma SA
-- -- -- -- $7.84
IVA
Inventiva SA
-- -$0.47 -- -- $11.13
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ESLOY
Essilorluxottica
$139.39 -- $127.3B 50.68x $2.14 0% 4.52x
CLLS
Cellectis SA
$1.58 $5.80 $158.1M -- $0.00 0% 3.74x
DBVT
DBV Technologies SA
$9.83 $15.52 $268.9M -- $0.00 0% --
GNFT
Genfit SA
$4.30 $10.17 $215M 32.57x $0.00 0% 2.98x
IPHA
Innate Pharma SA
$2.38 $7.84 $219.3M -- $0.00 0% 14.24x
IVA
Inventiva SA
$3.52 $11.13 $336.7M -- $0.00 0% 21.46x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ESLOY
Essilorluxottica
19.16% 0.597 8.98% 0.68x
CLLS
Cellectis SA
27.15% 0.907 37.63% 1.70x
DBVT
DBV Technologies SA
-- -3.919 -- --
GNFT
Genfit SA
-- 0.519 -- --
IPHA
Innate Pharma SA
55.22% -0.722 24.23% 2.76x
IVA
Inventiva SA
-145.15% -0.481 32.05% 0.43x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ESLOY
Essilorluxottica
-- -- 4.85% 5.92% -- --
CLLS
Cellectis SA
-- -$10.7M -22.9% -31.46% 65.62% -$1.8M
DBVT
DBV Technologies SA
-- -$26.6M -- -- -- -$19.7M
GNFT
Genfit SA
-- -- -- -- -- --
IPHA
Innate Pharma SA
-- -- -39.78% -72.79% -- --
IVA
Inventiva SA
-- -- -- -- -- --

Essilorluxottica vs. Competitors

  • Which has Higher Returns ESLOY or CLLS?

    Cellectis SA has a net margin of -- compared to Essilorluxottica's net margin of 46.57%. Essilorluxottica's return on equity of 5.92% beat Cellectis SA's return on equity of -31.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESLOY
    Essilorluxottica
    -- -- $52.6B
    CLLS
    Cellectis SA
    -- $0.08 $179.9M
  • What do Analysts Say About ESLOY or CLLS?

    Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 267.09%. Given that Cellectis SA has higher upside potential than Essilorluxottica, analysts believe Cellectis SA is more attractive than Essilorluxottica.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESLOY
    Essilorluxottica
    0 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is ESLOY or CLLS More Risky?

    Essilorluxottica has a beta of 1.078, which suggesting that the stock is 7.808% more volatile than S&P 500. In comparison Cellectis SA has a beta of 3.107, suggesting its more volatile than the S&P 500 by 210.711%.

  • Which is a Better Dividend Stock ESLOY or CLLS?

    Essilorluxottica has a quarterly dividend of $2.14 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 49.3% of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ESLOY or CLLS?

    Essilorluxottica quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $12.7M. Essilorluxottica's net income of -- is lower than Cellectis SA's net income of $5.9M. Notably, Essilorluxottica's price-to-earnings ratio is 50.68x while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 4.52x versus 3.74x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESLOY
    Essilorluxottica
    4.52x 50.68x -- --
    CLLS
    Cellectis SA
    3.74x -- $12.7M $5.9M
  • Which has Higher Returns ESLOY or DBVT?

    DBV Technologies SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of 5.92% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESLOY
    Essilorluxottica
    -- -- $52.6B
    DBVT
    DBV Technologies SA
    -- -$1.30 --
  • What do Analysts Say About ESLOY or DBVT?

    Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand DBV Technologies SA has an analysts' consensus of $15.52 which suggests that it could grow by 57.86%. Given that DBV Technologies SA has higher upside potential than Essilorluxottica, analysts believe DBV Technologies SA is more attractive than Essilorluxottica.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESLOY
    Essilorluxottica
    0 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is ESLOY or DBVT More Risky?

    Essilorluxottica has a beta of 1.078, which suggesting that the stock is 7.808% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -0.661, suggesting its less volatile than the S&P 500 by 166.125%.

  • Which is a Better Dividend Stock ESLOY or DBVT?

    Essilorluxottica has a quarterly dividend of $2.14 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 49.3% of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ESLOY or DBVT?

    Essilorluxottica quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than DBV Technologies SA's net income of -$27.1M. Notably, Essilorluxottica's price-to-earnings ratio is 50.68x while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 4.52x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESLOY
    Essilorluxottica
    4.52x 50.68x -- --
    DBVT
    DBV Technologies SA
    -- -- -- -$27.1M
  • Which has Higher Returns ESLOY or GNFT?

    Genfit SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of 5.92% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESLOY
    Essilorluxottica
    -- -- $52.6B
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About ESLOY or GNFT?

    Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 144.9%. Given that Genfit SA has higher upside potential than Essilorluxottica, analysts believe Genfit SA is more attractive than Essilorluxottica.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESLOY
    Essilorluxottica
    0 0 0
    GNFT
    Genfit SA
    1 0 0
  • Is ESLOY or GNFT More Risky?

    Essilorluxottica has a beta of 1.078, which suggesting that the stock is 7.808% more volatile than S&P 500. In comparison Genfit SA has a beta of 0.919, suggesting its less volatile than the S&P 500 by 8.105%.

  • Which is a Better Dividend Stock ESLOY or GNFT?

    Essilorluxottica has a quarterly dividend of $2.14 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 49.3% of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ESLOY or GNFT?

    Essilorluxottica quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than Genfit SA's net income of --. Notably, Essilorluxottica's price-to-earnings ratio is 50.68x while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 4.52x versus 2.98x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESLOY
    Essilorluxottica
    4.52x 50.68x -- --
    GNFT
    Genfit SA
    2.98x 32.57x -- --
  • Which has Higher Returns ESLOY or IPHA?

    Innate Pharma SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of 5.92% beat Innate Pharma SA's return on equity of -72.79%.

    Company Gross Margin Earnings Per Share Invested Capital
    ESLOY
    Essilorluxottica
    -- -- $52.6B
    IPHA
    Innate Pharma SA
    -- -- $68.9M
  • What do Analysts Say About ESLOY or IPHA?

    Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Innate Pharma SA has an analysts' consensus of $7.84 which suggests that it could grow by 229.27%. Given that Innate Pharma SA has higher upside potential than Essilorluxottica, analysts believe Innate Pharma SA is more attractive than Essilorluxottica.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESLOY
    Essilorluxottica
    0 0 0
    IPHA
    Innate Pharma SA
    1 1 0
  • Is ESLOY or IPHA More Risky?

    Essilorluxottica has a beta of 1.078, which suggesting that the stock is 7.808% more volatile than S&P 500. In comparison Innate Pharma SA has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.329%.

  • Which is a Better Dividend Stock ESLOY or IPHA?

    Essilorluxottica has a quarterly dividend of $2.14 per share corresponding to a yield of 0%. Innate Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 49.3% of its earnings as a dividend. Innate Pharma SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ESLOY or IPHA?

    Essilorluxottica quarterly revenues are --, which are smaller than Innate Pharma SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than Innate Pharma SA's net income of --. Notably, Essilorluxottica's price-to-earnings ratio is 50.68x while Innate Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 4.52x versus 14.24x for Innate Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESLOY
    Essilorluxottica
    4.52x 50.68x -- --
    IPHA
    Innate Pharma SA
    14.24x -- -- --
  • Which has Higher Returns ESLOY or IVA?

    Inventiva SA has a net margin of -- compared to Essilorluxottica's net margin of --. Essilorluxottica's return on equity of 5.92% beat Inventiva SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ESLOY
    Essilorluxottica
    -- -- $52.6B
    IVA
    Inventiva SA
    -- -- -$34.6M
  • What do Analysts Say About ESLOY or IVA?

    Essilorluxottica has a consensus price target of --, signalling downside risk potential of --. On the other hand Inventiva SA has an analysts' consensus of $11.13 which suggests that it could grow by 216.33%. Given that Inventiva SA has higher upside potential than Essilorluxottica, analysts believe Inventiva SA is more attractive than Essilorluxottica.

    Company Buy Ratings Hold Ratings Sell Ratings
    ESLOY
    Essilorluxottica
    0 0 0
    IVA
    Inventiva SA
    6 1 0
  • Is ESLOY or IVA More Risky?

    Essilorluxottica has a beta of 1.078, which suggesting that the stock is 7.808% more volatile than S&P 500. In comparison Inventiva SA has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock ESLOY or IVA?

    Essilorluxottica has a quarterly dividend of $2.14 per share corresponding to a yield of 0%. Inventiva SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Essilorluxottica pays 49.3% of its earnings as a dividend. Inventiva SA pays out -- of its earnings as a dividend. Essilorluxottica's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios ESLOY or IVA?

    Essilorluxottica quarterly revenues are --, which are smaller than Inventiva SA quarterly revenues of --. Essilorluxottica's net income of -- is lower than Inventiva SA's net income of --. Notably, Essilorluxottica's price-to-earnings ratio is 50.68x while Inventiva SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Essilorluxottica is 4.52x versus 21.46x for Inventiva SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ESLOY
    Essilorluxottica
    4.52x 50.68x -- --
    IVA
    Inventiva SA
    21.46x -- -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Spotify a Millionaire-Maker Stock?
Is Spotify a Millionaire-Maker Stock?

Spotify (NYSE:SPOT) may seem like an expensive proposition trading closer…

What Is a Millionaire-Maker Stock?
What Is a Millionaire-Maker Stock?

From time to time, investors will run across the term…

5 Investors to Follow Other Than Warren Buffett
5 Investors to Follow Other Than Warren Buffett

There is no doubt that Warren Buffett is one of…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 37x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
63
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 40x

Alerts

Buy
52
QDEL alert for May 10

QuidelOrtho [QDEL] is down 0.22% over the past day.

Buy
97
NGVC alert for May 10

Natural Grocers by Vitamin Cottage [NGVC] is up 30.26% over the past day.

Buy
66
ONTO alert for May 10

Onto Innovation [ONTO] is down 30.17% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock